Phoreus Biotech

About:

Phoreus Biotech produces peptide nanocarrier platforms that can revolutionize the human pharma, ag biotech, and cell transfection industries

Website: https://phoreusbiotech.com

Description:

Phoreus Biotech provides next-generation, peptide nanocarrier platforms that can revolutionize the development of animal health technologies. Our Branched Amphipathic Peptide Capsules (BAPC™) and Corralling Amphipathic Peptide Colloids (CAPC™) offer substantially increased efficacy in the creation and delivery of genetic vaccines, cancer therapies, antibiotics, and diagnostics. Current research and commercial entities have prioritized employing nanocarrier technology to both create new applications (e.g., mRNA and plasmid vaccines) and enhance the delivery/efficacy of current chemical/active ingredients (e.g., traditional antibiotics) while reducing negative effects and environmental impact. Our BAPC and CAPC platforms offer significant advantages in developing new commercially viable products and improving established product lines. The current nanocarriers available today have many limitations in these applications, and there are no competitors using self-assembling, customizable peptide nanocarriers that deliver our unique benefits.

Total Funding Amount:

$3.13M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Olathe, Kansas, United States

Founded Date:

2018-01-01

Contact Email:

info(AT)phoreusbiotech.com

Founders:

Randall Tosh

Number of Employees:

1-10

Last Funding Date:

2022-05-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai